On June 1, 2023, PNC Financial Services Group Inc. announced that it had reduced its stake in Exact Sciences Co. by 19.4% during the fourth quarter. According to PNC’s most recent 13F filing with the Securities and Exchange Commission, the company owned 17,024 shares of Exact Sciences stock after selling 4,106 shares during the period. As of its last SEC filing, PNC’s holdings in Exact Sciences were valued at approximately $843,000.
Exact Sciences Corp., headquartered in Madison, WI., is a leading cancer screening and diagnostics company that is focused on early detection and prevention of certain forms of cancer. The firm offers an innovative non-invasive screening test called Cologuard for early detection of colorectal cancer and pre-cancer as well as Oncotype DX.
Exact Sciences’ stock is traded on the NASDAQ under the ticker symbol EXAS and opened at $81.58 on Thursday with a market capitalization of $14.72 billion, a PE ratio of -27.94 and a beta of 1.41. The firm’s fifty-day moving average price was $70.79 while its two-hundred day moving average price was $61.95. Despite some near-term volatility due to PNC selling off shares of their holdings in this promising firm; EXACT Science’s outlook appears bullish.
Over the past year alone, Exact Sciences has achieved remarkable growth in terms of both revenue and overall performance across various metrics which can make it an attractive option for investors looking to diversify their portfolio.
In conclusion, while PNC may have reduced its stake in Exact Sciences there are still plenty of reasons to remain optimistic about this cancer screening and diagnostic company into the foreseeable future as it continues to innovate using emerging technologies in its field with potentially profound implications for patients worldwide suffering from serious illnesses including many types of cancer which can have such a significant impact on patients lives and well-being.
Investors Adjust Holdings in Exact Sciences Corporation as Insiders Sell Shares
Exact Sciences Corporation has recently seen a modification of holdings among large investors. Desjardins Global Asset Management Inc., Quent Capital LLC, Baldwin Brothers LLC MA, Signaturefd LLC, and Benjamin Edwards Inc. all have adjusted their holdings of the medical research company’s stock in recent quarters. As of now, institutional investors possess 90.30% of the company’s stock.
However, the sale of shares by insiders Jacob A. Orville and General Counsel James Herriot has also come to light. Orville sold 5,000 shares on March 3rd at an average price of $65.00 each, while General Counsel James Herriott sold 1,300 shares on May 10th for an average price of $79.85 per share. Insiders have sold a total of 19,387 shares over the past three months.
The Exact Sciences Corporation specializes in cancer screening and diagnostics with a focus on early detection and prevention methods for certain forms of cancer through non-invasive testing using Cologuard and Oncotype DX.
In terms of financials, Exact Sciences posted its earnings results on May 9th and reported earnings per share at ($0.42), which exceeded analysts’ expectations by $0.37 per share. The company’s revenue also surpassed expectations by coming in at $602 million dollars compared to analysts’ predictions of $543 million dollars.
Analysts have had mixed opinions regarding Exact Sciences Corporation’s future outlook throughout the year with some rating it as a “moderate buy” while others assign it to be “neutral.” Citigroup raised its price target from $90 to $100 dollars but Credit Suisse Group maintained its neutral rating with a target price set at $70 per share.
Exact Sciences currently trades under NASDAQ:EXAS and was established February 10th, 1995 with headquarters located in Madison, Wisconsin.The firm continues to work towards developing innovative solutions for early cancer detection and may continue to attract the interest of investors hoping to capitalize on this goal.
Source: beststocks.com
